ATE519503T1 - Verfahren zur behandlung von patienten mit hepatitis c - Google Patents

Verfahren zur behandlung von patienten mit hepatitis c

Info

Publication number
ATE519503T1
ATE519503T1 AT08831728T AT08831728T ATE519503T1 AT E519503 T1 ATE519503 T1 AT E519503T1 AT 08831728 T AT08831728 T AT 08831728T AT 08831728 T AT08831728 T AT 08831728T AT E519503 T1 ATE519503 T1 AT E519503T1
Authority
AT
Austria
Prior art keywords
hepatitis
treating patients
relapsed
infection
combination
Prior art date
Application number
AT08831728T
Other languages
English (en)
Inventor
Janice K Albrecht
Clifford A Brass
Robert Orville Ralston
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40262964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE519503(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE519503T1 publication Critical patent/ATE519503T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT08831728T 2007-09-14 2008-09-11 Verfahren zur behandlung von patienten mit hepatitis c ATE519503T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99375307P 2007-09-14 2007-09-14
US99876207P 2007-10-12 2007-10-12
US149407P 2007-10-30 2007-10-30
PCT/US2008/010626 WO2009038663A1 (en) 2007-09-14 2008-09-11 Method of treating hepatitis c patients

Publications (1)

Publication Number Publication Date
ATE519503T1 true ATE519503T1 (de) 2011-08-15

Family

ID=40262964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08831728T ATE519503T1 (de) 2007-09-14 2008-09-11 Verfahren zur behandlung von patienten mit hepatitis c

Country Status (18)

Country Link
US (1) US20100226885A1 (de)
EP (2) EP2061513B1 (de)
JP (1) JP2010539165A (de)
CN (1) CN101883590A (de)
AT (1) ATE519503T1 (de)
AU (1) AU2008301981A1 (de)
CA (1) CA2699280A1 (de)
CY (1) CY1112116T1 (de)
DK (1) DK2061513T3 (de)
ES (1) ES2369321T3 (de)
HK (1) HK1129315A1 (de)
HR (1) HRP20110637T1 (de)
MX (1) MX2010002909A (de)
NZ (1) NZ583825A (de)
PL (1) PL2061513T3 (de)
PT (1) PT2061513E (de)
SI (1) SI2061513T1 (de)
WO (1) WO2009038663A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
EP2704570A4 (de) * 2011-05-04 2015-02-18 Merck Sharp & Dohme Wirkstoffe, pharmazeutische zusammensetzungen damit und verfahren zu ihrer herstellung
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2012332827A1 (en) 2011-10-31 2014-05-15 Gilead Pharmasset Llc Methods and compositions for treating hepatitis C virus
AU2012346217B2 (en) * 2011-11-29 2016-02-04 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013116592A1 (en) 2012-02-01 2013-08-08 Kadmon Pharmaceuticals, Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000051631A2 (en) * 1999-03-02 2000-09-08 Schering Corporation Pegylated alpha interferon for hiv therapy
PL206255B1 (pl) * 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PT1730110E (pt) 2004-02-27 2010-09-14 Schering Corp Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c
WO2006016930A2 (en) * 2004-05-14 2006-02-16 Intermune, Inc. Methods for treating hcv infection
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
US20070274951A1 (en) 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen

Also Published As

Publication number Publication date
EP2489369A1 (de) 2012-08-22
AU2008301981A1 (en) 2009-03-26
PT2061513E (pt) 2011-10-17
US20100226885A1 (en) 2010-09-09
CA2699280A1 (en) 2009-03-26
EP2061513B1 (de) 2011-08-10
PL2061513T3 (pl) 2011-12-30
CY1112116T1 (el) 2015-11-04
MX2010002909A (es) 2010-03-30
SI2061513T1 (sl) 2011-11-30
DK2061513T3 (da) 2011-11-21
HRP20110637T1 (hr) 2011-10-31
HK1129315A1 (en) 2009-11-27
ES2369321T3 (es) 2011-11-29
JP2010539165A (ja) 2010-12-16
WO2009038663A1 (en) 2009-03-26
CN101883590A (zh) 2010-11-10
EP2061513A1 (de) 2009-05-27
NZ583825A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE474602T1 (de) Verfahren zur behandlung von hiv-infektion
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE112007002054A5 (de) Herstellung, Verfahren und Verwendung von wirkstofffreisetzenden Medizinprodukten zur permanenten Offenhaltung von Blutgefässen
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
ATE443769T1 (de) Impfstoff zur prävention und behandlung von einer hiv-infektion
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
ATE548044T1 (de) Kombinationstherapie zur behandlung von hiv- infektionen
DE602004017283D1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
ATE479716T1 (de) Copolymerisate und ihre verwendung zur behandlung von flexiblen substraten
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ATE503500T1 (de) Verfahren zur keimreduktion von abformmaterialien
DE602004016126D1 (de) Aplidine zur behandlung von multiplem myelom
DE112006001557A5 (de) Verfahren zur Abformung des Kiefers bzw. der Kiefersituation bei der zahnmedizinischen Behandlung von Patienten
ATE478707T1 (de) Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
ATE435220T1 (de) Verfahren zur behandlung von natriumhaltigen schwerrückständen und den auf diese weise hergestellter treibstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2061513

Country of ref document: EP